

The Alzheimer's Association Transforming Alzheimer's Disease Therapies Through Collaboration

James Hendrix, PhD
Director, Global Science Initiatives

alzheimer's  association®

THE BRAINS BEHIND SAVING YOURS.™

The Alzheimer's Epidemic Continues to Grow

5.3


million Americans of **ALL** Ages
will have Alzheimer's in 2015

6

Of the top 10 killers,
Alzheimer's is the
only one that cannot
be prevented, cured
or even slowed.

6TH LEADING
CAUSE OF DEATH
IN THE U.S.


Source: Centers for Disease Control and Prevention (cdc.gov/rchs/fastats/leading-causes-of-death.html)



Total cost of care for those with Alzheimer's,
with more than two-thirds paid by Medicare and Medicaid

Alzheimer's Crisis In the Baby Boom Generation

- If no way to stop or slow the progression of the disease
 - More than 28 million Baby Boomers will develop Alzheimer's by 2050
 - Will account for nearly 25% of Medicare spending by 2050



alzheimer's  association®

International Research 
GRANT PROGRAM

Research Roundtable



alzheimer's  association®



Connector • Convener • Funder

The Global Leader in Alzheimer's Research

alzheimer's  association®

trialmatch™



alzheimer's  association®



alzheimer's  association®

Alzheimer's & Dementia®
THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION


alzheimer's  association®

THE BRAINS BEHIND SAVING YOURS.™

Alzheimer's Association Public Private Partnerships



LEARN



JT Chien et al. *Journal of Alz Dis* 2013

- Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN)
- Natural history study of 400 people with low/intermediate levels of amyloid
- Leveraging the A4 trial
- ***Largest award ever given by Alzheimer's Association***
- ***First funded tau imaging study***

Alzheimer's Association / CAMD Partnerships

Biomarkers & Data Sharing



alzheimer's 
association®

Global Biomarkers
Standardization Consortium
(GBSC)



AD Biomarkers Team

AD HV MRI Biomarker Team

Pre-dementia Clinical Outcome
Assessment Tool Project (pCOA)

CAMD AD Database

Grant Partnerships: Biomarkers Across Neurodegenerative Diseases (BAND)

- GOAL: To stimulate analyses across Alzheimer's and Parkinson's to engage in further data analysis of existing research information to advance biomarker discovery, standardization of assays, genetic profiles, and imaging modalities.
- Leverage data from ADNI and PPMI
- First of its kind collaboration with Michael J. Fox Foundation & Weston Brain Institute
- Awarded 9 projects

alzheimer's  association®


THE MICHAEL J. FOX FOUNDATION
FOR PARKINSON'S RESEARCH

 WESTON
BRAIN INSTITUTE

alzheimer's  association®

THE BRAINS BEHIND SAVING YOURS.™

Grant Partnerships: Mechanisms of Cellular Death in Neurodegeneration (MEND)

alzheimer's 
association®

Alzheimer's
Research UK
Defeating Dementia

 **WESTON**
BRAIN INSTITUTE

- GOAL: To discover and understand mechanisms and pathophysiological processes by which brain cell loss is mediated in disease and thereby seek insights and potential targets for therapeutic interventions that would sustain healthy brain function.
- Funding international from funding organizations in three countries
- Awards to be announced by 10/30
- Alz.org/MEND


alzheimer's  association®

THE BRAINS BEHIND SAVING YOURS.™

IDEAS (*Imaging Dementia Evidence for Amyloid Scanning*) STUDY


- 4-year, \$100 million Alzheimer's research
- Alzheimer's Association and American College of Radiology (ACR).
- Goal: To determine clinical usefulness, value in diagnosing Alzheimer's (and other dementias) of a brain PET scan that detects amyloid plaques – a core feature of AD.
- 18,488 Medicare beneficiaries, age 65 or older, who have uncertain diagnosis will be enrolled over 24 months at approximately 200 sites throughout the United States.
- Data from this study will help determine if Medicare will reimburse the cost of amyloid PET scans for diagnostically uncertain cases. Medicare does not currently cover amyloid PET scans.

IDEAS
Imaging Dementia—Evidence
For Amyloid Scanning



Vision for the Future

- Advances in understanding of AD progression via new biomarkers (i.e. Tau PET, Neurogranin, etc.)
- Expansion of open access data
- New treatment strategies (i.e. AD Prevention, Combination Therapy)
- New therapeutics coming?



THE END OF
ALZHEIMER'S
STARTS
WITH YOU

alzheimer's  association[®]

[alz.org](https://www.alz.org)